Fibromyalgia is not a nerve disease in the traditional sense, but it’s not purely a musculoskeletal condition either. It is classified as a central sensitivity syndrome, meaning the core problem lies in how your brain and spinal cord process pain signals. However, the picture is more complex than that label suggests: roughly half of people with fibromyalgia show measurable damage to the small nerve fibers in their skin, and growing evidence points to immune-related inflammation in the brain itself.
How Fibromyalgia Is Officially Classified
In the International Classification of Diseases (ICD-11), adopted in 2019, fibromyalgia falls under chronic widespread pain (code MG30.01). It is not grouped with neurological disorders like multiple sclerosis or peripheral neuropathy, nor with autoimmune diseases. Instead, it sits within a newer framework that recognizes chronic pain as its own category.
Among pain researchers, fibromyalgia is considered the prototypical central sensitivity syndrome, a term describing conditions where the central nervous system amplifies pain signals beyond what any tissue damage would explain. This means your nerves and spinal cord become stuck in a heightened state, reacting more strongly to stimuli that wouldn’t normally be painful. Other conditions in this family include chronic fatigue syndrome, irritable bowel syndrome, and tension-type headache.
What Happens Inside the Nervous System
The hallmark of fibromyalgia is abnormal central pain processing. Normally, your brain has built-in pathways that dial pain signals up or down depending on context. In fibromyalgia, the “volume knob” for pain gets turned up and stays there. This is driven by neurobiological changes that disrupt the balance between pathways that amplify pain and those that suppress it.
Brain imaging studies show concrete differences in how the brains of people with fibromyalgia are wired. Compared to healthy controls, there is decreased connectivity between key pain-processing areas and the rest of the brain. The thalamus, which acts as a relay station for sensory information, shows weaker connections to motor-planning regions. The insula, a region involved in pain awareness, communicates less effectively with areas responsible for movement and touch. These disrupted connections help explain why fibromyalgia pain feels so pervasive and why it often comes with cognitive difficulties sometimes called “fibro fog.”
There is also direct evidence of inflammation within the brain. A multi-site brain imaging study provided the first in vivo proof that immune cells called microglia are abnormally activated in people with fibromyalgia. Microglia are the brain’s resident immune cells, and when they become overactive, they release inflammatory signals that further sensitize nearby neurons. Cerebrospinal fluid from fibromyalgia patients contains elevated levels of inflammatory signaling molecules involved in communication between neurons and these immune cells, reinforcing the idea that low-grade neuroinflammation helps sustain the pain cycle.
The Small Fiber Neuropathy Overlap
One of the most significant findings in fibromyalgia research is that about half of patients have measurable damage to their small nerve fibers, the thin nerve endings that extend into the skin and detect pain, temperature, and light touch. A large meta-analysis covering 11 skin biopsy studies and 591 patients found that 50% of fibromyalgia patients had reduced nerve fiber density in the skin, consistent with a condition called small fiber neuropathy. Another 45% showed signs of damage to small fibers that control automatic body functions like heart rate and sweating.
This is determined through a skin punch biopsy, a simple procedure where a tiny sample of skin (2 to 3 millimeters across) is taken from the lower leg. The sample is examined under a microscope to count how many nerve fibers reach into the outer layer of skin. In one study, fibromyalgia patients had a median of 5 nerve fibers per millimeter at the lower leg, compared to 9.5 in healthy controls. The test is recommended by both American and European neurological guidelines for diagnosing small fiber neuropathy, and it carries a level A recommendation, the highest level of clinical evidence.
This finding matters because it means fibromyalgia may involve real, measurable nerve damage in a substantial portion of patients, not just altered pain processing in the brain. For clinicians, discovering small fiber neuropathy changed treatment plans in over half of cases where a biopsy was performed.
How Fibromyalgia Pain Differs From Nerve Damage Pain
Despite the overlap with small fiber neuropathy, fibromyalgia and classic nerve diseases feel different. Fibromyalgia pain is typically described as deep, widespread muscle soreness. About 25% of patients compare it to the aching feeling after intense exercise. It tends to affect large regions of the body simultaneously, and physical activity, rest, and warmth often help relieve it. Cold and stress tend to make it worse.
Nerve damage diseases like small fiber neuropathy, by contrast, produce superficial burning or stabbing pain concentrated in the hands and feet. Burning pain was reported by 85% of neuropathy patients compared to 42% of fibromyalgia patients. Stabbing pain appeared in 66% of neuropathy patients versus 25% of those with fibromyalgia. People with nerve damage also commonly experience tingling (68% vs. 17%), numbness (28% vs. 12%), and hypersensitivity to touch (13% vs. less than 1%). In neuropathy, temperature can both help and worsen symptoms in unpredictable ways, whereas fibromyalgia patients show more consistent triggers.
These differences matter because the two conditions require different treatment approaches. If you have fibromyalgia with predominantly burning, stabbing pain in your hands and feet along with tingling or numbness, it may be worth asking about small fiber neuropathy testing.
A Possible Autoimmune Connection
Recent research has raised the possibility that some cases of fibromyalgia involve the immune system attacking components of the nervous system. When antibodies (IgG) from fibromyalgia patients were injected into mice, the animals developed fibromyalgia-like symptoms. Those antibodies were found to bind to satellite glial cells, which are support cells that wrap around sensory neurons in structures called dorsal root ganglia, a critical relay point where pain signals enter the spinal cord.
Fibromyalgia patients with higher levels of these antibodies against satellite glial cells had more severe symptoms. However, not all patients showed elevated antibody levels, and direct antibody binding to neurons themselves was not widespread. This suggests an autoimmune mechanism may drive the condition in a subset of patients rather than in everyone with a fibromyalgia diagnosis. Identifying the specific targets these antibodies attack could eventually lead to blood tests that distinguish autoimmune fibromyalgia from other forms.
Why Treatments Target the Nervous System
The medications approved for fibromyalgia all work by changing how your nervous system processes signals, which makes sense given the condition’s neurological roots. One class works by boosting levels of serotonin and norepinephrine in the brain and spinal cord. These are the chemical messengers that power your body’s natural pain-suppression pathways. By strengthening those pathways, these medications help restore balance between the signals that amplify pain and those that dampen it.
Another class reduces the release of excitatory brain chemicals, particularly glutamate and substance P, two molecules that play central roles in pain transmission. These drugs work by blocking calcium channels on nerve cells, which prevents the cells from firing as readily and releasing their payload of pain-promoting chemicals. They also increase levels of GABA, the brain’s primary calming neurotransmitter, which helps with the anxiety and sleep disruption that accompany fibromyalgia.
The fact that these neurologically targeted treatments provide relief reinforces that fibromyalgia is, at its core, a disorder of the nervous system. It may not fit neatly into the category of a “nerve disease” like diabetic neuropathy or carpal tunnel syndrome, where a specific nerve or set of nerves is damaged. But the nervous system, from the small fibers in your skin to the immune cells in your brain, is deeply involved at every level.